Yes, cariprazine (Vraylar) significantly increases the risk of death and serious adverse events in dementia patients and should NOT be used in this population.
The FDA has issued a black box warning specifically stating that elderly patients with dementia-related psychosis treated with antipsychotic drugs, including cariprazine, are at increased risk of death, and Vraylar is NOT approved for treatment of patients with dementia-related psychosis 1.
Critical Safety Concerns
Mortality Risk
All antipsychotic medications, including cariprazine, carry consistent evidence of increased mortality in elderly dementia patients 2. This is the most serious concern and forms the basis of the FDA's black box warning on Vraylar 1.
Cerebrovascular Events
Beyond mortality, antipsychotics in dementia patients are associated with:
- Increased incidence of stroke and transient ischemic attacks 1
- The FDA label specifically warns about cerebrovascular adverse reactions in elderly patients with dementia-related psychosis 1
- Research shows the risk is particularly elevated in the first weeks of treatment, with a nearly 10-fold increased risk in the first week 3
Additional Adverse Events
Cariprazine poses multiple risks in dementia patients including:
- Extrapyramidal symptoms and akathisia (very common with cariprazine) 1
- Orthostatic hypotension and syncope - particularly dangerous given fall risk 1
- Metabolic changes including hyperglycemia, diabetes, dyslipidemia, and weight gain 1
- Neuroleptic malignant syndrome 1
- Tardive dyskinesia 1
Clinical Context
The 2016 APA guidelines emphasize that antipsychotic benefits in dementia are "at best small" while adverse effects are clinically significant 2. When antipsychotics are considered in dementia (which should be rare), they should only be used when:
- Symptoms are severe, dangerous, and/or cause significant distress 2
- Nonpharmacological interventions have been tried first 2
- Risks and benefits are thoroughly discussed with patient/surrogate decision-makers 2
Important Caveats
Cariprazine has a uniquely long half-life, meaning adverse reactions may not appear until several weeks after initiation and will persist for weeks after discontinuation 1. This makes it particularly problematic in dementia patients who need close monitoring.
Recent evidence shows that even commonly used antipsychotics like risperidone cause cerebrovascular events (median onset 4.3 weeks), cardiovascular events (median onset 4.8 weeks), and other serious adverse effects predominantly after 4 weeks of treatment 4. The risk is highest in older patients, males, and those with baseline cardiac issues 4.
Bottom Line
Do not prescribe cariprazine for dementia-related behavioral symptoms. The FDA explicitly prohibits this use, and the drug carries a black box warning for increased mortality in this population. If antipsychotic use is absolutely necessary for dangerous agitation or psychosis in dementia (after exhausting nonpharmacological approaches), other agents with more dementia-specific data should be considered at the lowest possible dose for the shortest duration, with intensive monitoring 2.